BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38085960)

  • 1. Immunohistochemical Expression of Lymphoid Enhancer-binding Factor 1 in Low-grade Endometrial Stromal Tumors.
    Niu S; Lu H; Li W; Hou Y
    Int J Gynecol Pathol; 2023 Nov; ():. PubMed ID: 38085960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.
    Przybyl J; Kidzinski L; Hastie T; Debiec-Rychter M; Nusse R; van de Rijn M
    Gynecol Oncol; 2018 May; 149(2):388-393. PubMed ID: 29544705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic use of nuclear beta-catenin expression for the assessment of endometrial stromal tumors.
    Jung CK; Jung JH; Lee A; Lee YS; Choi YJ; Yoon SK; Lee KY
    Mod Pathol; 2008 Jun; 21(6):756-63. PubMed ID: 18376386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of LEF1 to differentiate desmoid fibromatosis from its histologic mimics.
    Jobbagy S; Lozano-Calderon S; Mullen JT; Nielsen GP; Hung YP; Chebib I
    Virchows Arch; 2024 May; 484(5):807-813. PubMed ID: 38503969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas.
    Kurihara S; Oda Y; Ohishi Y; Kaneki E; Kobayashi H; Wake N; Tsuneyoshi M
    Mod Pathol; 2010 Feb; 23(2):225-34. PubMed ID: 19898427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of β-Catenin and LEF1 Immunohistochemical Stains in Desmoid-type Fibromatosis and its Selected Mimickers, With Unexpected Finding of LEF1 Positivity in Scars.
    Zou Y; Zhang Y; Church J; Liu X
    Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):648-653. PubMed ID: 28027119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.
    Tandon B; Peterson L; Gao J; Nelson B; Ma S; Rosen S; Chen YH
    Mod Pathol; 2011 Nov; 24(11):1433-43. PubMed ID: 21685909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/β-catenin signaling.
    Huang X; Zhong R; He X; Deng Q; Peng X; Li J; Luo X
    IUBMB Life; 2019 Feb; 71(2):223-234. PubMed ID: 30452118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Expression of LEF1 and β-Catenin in Invasive Micropapillary Carcinoma of the Breast is Associated With Lymphovascular Invasion and Lymph Node Metastasis.
    Dolezal D; Zhang X; Harigopal M
    Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):557-565. PubMed ID: 35960138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms.
    McCluggage WG; Sumathi VP; Maxwell P
    Histopathology; 2001 Sep; 39(3):273-8. PubMed ID: 11532038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte nuclear factor 1β suppresses canonical Wnt signaling through transcriptional repression of lymphoid enhancer-binding factor 1.
    Chan SC; Hajarnis SS; Vrba SM; Patel V; Igarashi P
    J Biol Chem; 2020 Dec; 295(51):17560-17572. PubMed ID: 33453998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The osteogenic differentiation of human adipose-derived stem cells is regulated through the let-7i-3p/LEF1/β-catenin axis under cyclic strain.
    Luo Y; Ge R; Wu H; Ding X; Song H; Ji H; Li M; Ma Y; Li S; Wang C; Du H
    Stem Cell Res Ther; 2019 Nov; 10(1):339. PubMed ID: 31753039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canonical Wnt/β-catenin signaling activation in soft-tissue sarcomas: A comparative study of synovial sarcoma and leiomyosarcoma.
    Briski LM; Thomas DG; Patel RM; Lawlor ER; Chugh R; McHugh JB; Lucas DR
    Rare Tumors; 2018; 10():2036361318813431. PubMed ID: 30505422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and colocalization of β-catenin and lymphoid enhancing factor-1 in prostate cancer progression.
    Bauman TM; Vezina CM; Ricke EA; Halberg RB; Huang W; Peterson RE; Ricke WA
    Hum Pathol; 2016 May; 51():124-33. PubMed ID: 27067790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNAIL1 employs β-Catenin-LEF1 complexes to control colorectal cancer cell invasion and proliferation.
    Freihen V; Rönsch K; Mastroianni J; Frey P; Rose K; Boerries M; Zeiser R; Busch H; Hecht A
    Int J Cancer; 2020 Apr; 146(8):2229-2242. PubMed ID: 31463973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors.
    Grumolato L; Liu G; Haremaki T; Mungamuri SK; Mong P; Akiri G; Lopez-Bergami P; Arita A; Anouar Y; Mlodzik M; Ronai ZA; Brody J; Weinstein DC; Aaronson SA
    PLoS Genet; 2013; 9(8):e1003603. PubMed ID: 23966864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of LEF1 by MYC activates the WNT pathway and maintains cell proliferation.
    Hao YH; Lafita-Navarro MC; Zacharias L; Borenstein-Auerbach N; Kim M; Barnes S; Kim J; Shay J; DeBerardinis RJ; Conacci-Sorrell M
    Cell Commun Signal; 2019 Oct; 17(1):129. PubMed ID: 31623618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant beta-catenin and LEF1 expression may predict the clinical outcome for patients with oropharyngeal cancer.
    Papagerakis P; Pannone G; Shabana AH; Depondt J; Santoro A; Ghirtis K; Berdal A; Papagerakis S
    Int J Immunopathol Pharmacol; 2012; 25(1):135-46. PubMed ID: 22507326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma.
    Ravindran A; Kurtin PJ; King RL; Yuan J; Feldman AL; Rech KL; McPhail ED; Parikh SA; Ding W; Shi M
    Hum Pathol; 2022 Jul; 125():2-10. PubMed ID: 35421421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.